97% of vaccinated persons can produce neutralizing antibodies after 3 doses

The Phase 1 and Phase 2 clinical trial results of the recombinant protein subunit vaccine (ZF2001) developed by the Gaofu team of the Institute of Microbiology of the Chinese Academy of Sciences in conjunction with Anhui Zhifeilongkoma Biopharmaceutical Co.

At present, there are a variety of vaccines against the new crown pneumonia epidemic in the world, but they still cannot meet the needs of people for vaccination.

It is understood that the ZF2001 vaccine is based on the dimer concept of the previous Middle East Respiratory Syndrome (MERS) Coronavirus Spike Protein (S) Receptor Binding Domain (RBD), and the new coronavirus RBD is designed into a dimer (RBD- dimer) antigen, which successfully retained the efficacy of the vaccine, and the neutralizing antibody titer after immunization of mice was higher than that of monomer immunization.

A total of 950 healthy adults aged 18 to 59 years of age were recruited for the vaccine in two phases of clinical trials in China.

The research results show that the vaccine has good tolerability and immunogenicity.

In addition, in February this year, the Gaofu team released part of the results of the international phase 3 clinical trial in bioRxiv, showing the neutralizing effect of the domestic recombinant protein subunit new crown vaccine ZF2001 on the new South African variant (501Y.

The results show that although the vaccine's serum has a slight decrease in the neutralizing effect of the new South African variant, it still retains most of the neutralizing activity, suggesting that the vaccine still has a protective effect on the new South African variant.

Currently, this vaccine is undergoing international multi-center phase 3 clinical trials in Uzbekistan, Indonesia, Pakistan and Ecuador, and was approved for registration in Uzbekistan on March 1 this year.

Related paper information org/10.